These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 26514681

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
    Harringer S, Hejl M, Enyedy ÉA, Jakupec MA, Galanski MS, Keppler BK, Dyson PJ, Varbanov HP.
    Dalton Trans; 2021 Jun 21; 50(23):8167-8178. PubMed ID: 34031671
    [Abstract] [Full Text] [Related]

  • 23. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
    Jayawardhana AMDS, Bhandari S, Kaspi-Kaneti AW, Kshetri M, Qiu Z, Cheline M, Shen H, Dunietz BD, Zheng YR.
    Dalton Trans; 2023 Aug 08; 52(31):10942-10950. PubMed ID: 37490033
    [Abstract] [Full Text] [Related]

  • 27. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
    Huo S, Shen S, Liu D, Shi T.
    J Phys Chem B; 2012 Jun 07; 116(22):6522-8. PubMed ID: 22574871
    [Abstract] [Full Text] [Related]

  • 28. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.
    Varbanov HP, Jakupec MA, Roller A, Jensen F, Galanski MS, Keppler BK.
    J Med Chem; 2013 Jan 10; 56(1):330-44. PubMed ID: 23214999
    [Abstract] [Full Text] [Related]

  • 31. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
    Najjar A, Rajabi N, Karaman R.
    Curr Pharm Des; 2017 Jan 10; 23(16):2366-2376. PubMed ID: 28155621
    [Abstract] [Full Text] [Related]

  • 32. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy.
    Xiao H, Song H, Zhang Y, Qi R, Wang R, Xie Z, Huang Y, Li Y, Wu Y, Jing X.
    Biomaterials; 2012 Nov 10; 33(33):8657-69. PubMed ID: 22938766
    [Abstract] [Full Text] [Related]

  • 33. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.
    Thiabaud G, McCall R, He G, Arambula JF, Siddik ZH, Sessler JL.
    Angew Chem Int Ed Engl; 2016 Oct 04; 55(41):12626-31. PubMed ID: 27377046
    [Abstract] [Full Text] [Related]

  • 34. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
    Yap SQ, Chin CF, Hong Thng AH, Pang YY, Ho HK, Ang WH.
    ChemMedChem; 2017 Feb 20; 12(4):300-311. PubMed ID: 28028938
    [Abstract] [Full Text] [Related]

  • 35. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z, Wang H, Li Y, Qin Y, Xu L, Bowers DJ, Gangoda M, Li X, Yang HB, Zheng YR.
    Chem Commun (Camb); 2018 Jan 18; 54(7):731-734. PubMed ID: 29303526
    [Abstract] [Full Text] [Related]

  • 36. Anticancer platinum (IV) prodrugs with novel modes of activity.
    Chin CF, Wong DY, Jothibasu R, Ang WH.
    Curr Top Med Chem; 2011 Jan 18; 11(21):2602-12. PubMed ID: 22039869
    [Abstract] [Full Text] [Related]

  • 37. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X, Yu Z.
    Chem Commun (Camb); 2018 May 22; 54(42):5369-5372. PubMed ID: 29744485
    [Abstract] [Full Text] [Related]

  • 38. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 39. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D.
    Dalton Trans; 2016 Aug 16; 45(33):12983-91. PubMed ID: 27214873
    [Abstract] [Full Text] [Related]

  • 40. Fluorogenic platinum(IV) complexes as potential predictors for the design of hypoxia-activated platinum(IV) prodrugs.
    Marsh JW, Hacker L, Huang S, Boulet MHC, White JRG, Martin LAW, Yeomans MA, Han HH, Diez-Perez I, Musgrave RA, Hammond EM, Sedgwick AC.
    Dalton Trans; 2024 Sep 10; 53(35):14811-14816. PubMed ID: 39169877
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.